171 related articles for article (PubMed ID: 37147936)
1. Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer.
Dutt M; Hartel G; Richards RS; Shah AK; Mohamed A; Apostolidou S; Gentry-Maharaj A; ; Hooper JD; Perrin LC; Menon U; Hill MM
Proteomics Clin Appl; 2023 Jul; 17(4):e2200114. PubMed ID: 37147936
[TBL] [Abstract][Full Text] [Related]
2. Semi-Automated Lectin Magnetic Bead Array (LeMBA) for Translational Serum Glycoprotein Biomarker Discovery and Validation.
Dutt M; Duong MN; Bringans S; Richards RS; Lipscombe R; Hill MM
Methods Mol Biol; 2023; 2628():395-411. PubMed ID: 36781799
[TBL] [Abstract][Full Text] [Related]
3. Screening by Q Exactive liquid chromatography/tandem mass spectrometry identified Choline, 25-hydroxyvitamin D2, and SM(d18:0/16:1(9Z) (OH)) as biomarkers for high-grade serous ovarian cancer.
Li J; Liu D; Cui M; Wei Z
J Proteomics; 2024 May; 299():105154. PubMed ID: 38471622
[TBL] [Abstract][Full Text] [Related]
4. High-throughput lectin magnetic bead array-coupled tandem mass spectrometry for glycoprotein biomarker discovery.
Choi E; Loo D; Dennis JW; O'Leary CA; Hill MM
Electrophoresis; 2011 Dec; 32(24):3564-75. PubMed ID: 22180208
[TBL] [Abstract][Full Text] [Related]
5. Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.
Shah AK; Cao KA; Choi E; Chen D; Gautier B; Nancarrow D; Whiteman DC; Saunders NA; Barbour AP; Joshi V; Hill MM
Mol Cell Proteomics; 2015 Nov; 14(11):3023-39. PubMed ID: 26404905
[TBL] [Abstract][Full Text] [Related]
6. Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry.
Huh S; Kang C; Park JE; Nam D; Kim SI; Seol A; Choi K; Hwang D; Yu MH; Chung HH; Lee SW; Kang UB
J Proteome Res; 2022 Sep; 21(9):2146-2159. PubMed ID: 35939567
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
[TBL] [Abstract][Full Text] [Related]
8. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
[TBL] [Abstract][Full Text] [Related]
9. Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.
Ryu J; Boylan KLM; Twigg CAI; Evans R; Skubitz APN; Thomas SN
Clin Proteomics; 2024 Jan; 21(1):1. PubMed ID: 38172678
[TBL] [Abstract][Full Text] [Related]
10. Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma.
Kim SI; Hwangbo S; Dan K; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Han D; Lee M
Mol Cell Proteomics; 2023 Mar; 22(3):100502. PubMed ID: 36669591
[TBL] [Abstract][Full Text] [Related]
11. Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS.
Wu J; Xie X; Liu Y; He J; Benitez R; Buckanovich RJ; Lubman DM
J Proteome Res; 2012 Sep; 11(9):4541-52. PubMed ID: 22827608
[TBL] [Abstract][Full Text] [Related]
12. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers.
Farinella F; Merone M; Bacco L; Capirchio A; Ciccozzi M; Caligiore D
Sci Rep; 2022 Feb; 12(1):3041. PubMed ID: 35197484
[TBL] [Abstract][Full Text] [Related]
14. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
[TBL] [Abstract][Full Text] [Related]
15. Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.
Wang B; Chao S; Guo B
J Clin Lab Anal; 2022 Feb; 36(2):e24165. PubMed ID: 34997982
[TBL] [Abstract][Full Text] [Related]
16. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study.
Kandimalla R; Wang W; Yu F; Zhou N; Gao F; Spillman M; Moukova L; Slaby O; Salhia B; Zhou S; Wang X; Goel A
Clin Cancer Res; 2021 Aug; 27(15):4277-4286. PubMed ID: 34035068
[TBL] [Abstract][Full Text] [Related]
17. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
[TBL] [Abstract][Full Text] [Related]
20. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
[No Abstract] [Full Text] [Related]
[Next] [New Search]